Meta Platforms Inc vs Viatris Inc — how do they compare? Meta Platforms Inc trades at $601.44 (market cap $1.52T), while Viatris Inc trades at $16.28 (market cap $18.69B). The key difference: Meta Platforms Inc is far larger — about 81.3× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.95%). Which is the better fit depends on your goals.
| META | VTRS | |
|---|---|---|
Market Cap | $1.52T | $18.69B |
Volume | 24,093,972 | — |
Sector | Media | Health |
52-Week High | $790.00 | $17.86 |
52-Week Low | $525.72 | $9.49 |
Enterprise Value | $1.54T | $30.81B |
Dividend Yield | 0.35% | 2.95% |
Signals from Pluang's Aura AI — not financial advice
META trades at $594.92, up 0.48% with strong fundamentals including 81.75% gross margins and 29.84% net income margin. Recent Q1 2026 earnings beat expectations ($10.44 vs $6.70), though Q2 2026 missed. Technical indicators show bearish momentum with RSI at 96.23 suggesting overbought conditions. The company launched Muse Spark AI model and faces ongoing legal challenges regarding youth addiction lawsuits.
Outlook remains positive with analyst consensus price target of $761.95 (28% upside) and 79% buy ratings. Key risks include regulatory lawsuits, aggressive AI capex spending ($102B in 2025), and competitive pressures. Revenue growth continues at 22% year-over-year to $201B, supporting long-term investment thesis despite near-term technical weakness.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Meta Platforms Inc., doing business as Meta and previously known as Facebook Inc. It's a company that acts as a parent platform for Facebook, Messenger, Instagram, Whatsapp, Oculus and other subsidiaries. Among these platforms, Facebook is the number one social media platform in terms of the number of active users.
Read more on META →Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →